The global idiopathic thrombocytopenic purpura therapeutics market was valued at US$ 587.0 Million in 2021, and is projected to be valued at US$ 620.5 Million in 2022. During the 2022-2032 period of assessment, demand is expected to rise at a 5.0% value CAGR, likely to reach US$ 1.0 Billion by the end of the said forecast period.
Overall, the idiopathic thrombocytopenic purpura therapeutics landscape is poised to yield an absolute dollar opportunity worth US$ 390.9 Million until 2032. Sales of Idiopathic Thrombocytopenic Purpura Therapeutics will continue to flourish, with a documented CAGR of 5.6% from 2015-2021.
Request For Sample Report- https://www.factmr.com/connectus/sample?flag=S&rep_id=7449
Competitive Landscape
- In February 2019, Paras Biopharmaceuticals Finland Oy announced the successful development of biologically active Romiplostim.
- In April 2018, U.S Food and Drug Administration (FDA) approved the therapeutic use of TAVALISSE developed by Rigel Pharmaceuticals, Inc. as the second line of treatment for ITP.
- In March 2018, Dova Pharmaceuticals, along with its wholly-owned subsidiary AkaRx, Inc. entered into a distribution and development rights agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. For DOPTELET in China and Hong Kong.
Key Segments Covered in the Idiopathic Thrombocytopenic Purpura Therapeutics Industry Report
-
Idiopathic Thrombocytopenic Purpura Therapeutics Market by Product Type :
- Corticosteroids-based Idiopathic Thrombocytopenic Purpura Therapeutics
- Intravenous Immunoglobulins-based Idiopathic Thrombocytopenic Purpura Therapeutics
- Anti-D Immunoglobulin-based Idiopathic Thrombocytopenic Purpura Therapeutics
- Thrombopoietin Receptor Agonists (TPO-RA) based Idiopathic Thrombocytopenic Purpura
- Other Idiopathic Thrombocytopenic Purpura Therapeutic Products
-
Idiopathic Thrombocytopenic Purpura Therapeutics Market by Distribution Channel :
- Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Drug Stores
- Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Retail Pharmacies
- Idiopathic Thrombocytopenic Purpura Therapeutic Product Sales via Other Distribution Channels
-
Idiopathic Thrombocytopenic Purpura Therapeutics Market by Treatment Type :
- Oral Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics
- Prednisone
- Rituximab
- Azathioprine
- Eltrombopag
- Splenectomy-based Idiopathic Thrombocytopenic Purpura Therapeutics
- Intravenous Immunoglobulin (IVIG)
- Anti-D Immunoglobulin
- Thrombopoietin Receptor Agonists
- Oral Corticosteroids Idiopathic Thrombocytopenic Purpura Therapeutics
-
Idiopathic Thrombocytopenic Purpura Therapeutics Market by Region :
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
